住院成人疫苗可预防肺炎链球菌疾病负担:加拿大免疫研究网络(CIRN)严重结局监测(SOS)网络研究
该研究在加拿大五省医院对住院成人开展CAPSpn和IPD主动监测(2010年12月至2013年)。共识别4769例全因CAP和81例IPD(非CAP),3851例CAP进行了肺炎链球菌实验室检测,14.3%为CAPSpn;四项检测均完成的CAP中23.2%(144/621)检出肺炎链球菌。PCV13型CAPSpn占CAP的7.0%至14.8%,疫苗可预防肺炎链球菌CAP和IPD是加拿大住院成人显著发病和死亡原因。
要点
- 3851例住院CAP中14.3%为肺炎链球菌CAP(CAPSpn)。
- 四项检测均完成的621例CAP中23.2%(144/621)检出肺炎链球菌。
- 可分型的CAPSpn或IPD以血清型3、7F、19A和22F为主。
核心结论
- 疫苗可预防肺炎链球菌CAP和IPD是加拿大婴儿PCV13免疫规划后三年内住院成人显著发病和死亡原因。
研究设计与样本
- 2010年12月至2013年在加拿大五省医院对住院成人CAPSpn和IPD开展主动监测。
- CAPSpn通过痰培养、血培养、市售泛肺炎链球菌尿抗原检测(UAD)或血清型特异性UAD识别。
- 血清型分布采用Quellung反应、培养分离株PCR分型或13价肺炎链球菌结合疫苗(PCV13)血清型特异性UAD检测表征。
主要发现
- 共识别4769例全因CAP和81例IPD(非CAP)。
- 4769例全因CAP中3851例进行肺炎链球菌实验室检测,14.3%为CAPSpn。
- 四项诊断检测均完成的CAP中肺炎链球菌检出率为23.2%(144/621)。
- CAPSpn病例随年龄增加,疾病负担体现在需要机械通气、入住重症监护室和30天死亡率。
- 可分型的CAPSpn或IPD结果中观察到血清型3、7F、19A和22F占优势。
关键数值与推荐
- 至少进行一项肺炎链球菌检测的CAP病例中,PCV13型肺炎链球菌所致CAP比例为7.0%。
- 四项诊断检测均完成的CAP病例中,PCV13型肺炎链球菌所致CAP比例为14.8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal community acquired pneumonia (CAPSpn) and invasive pneumococcal disease (IPD) cause significant morbidity and mortality worldwide. Although childhood immunization programs have reduced the overall burden of pneumococcal disease, there is insufficient data in Canada to inform immunization policy in immunocompetent adults. This study aimed to describe clinical outcomes of pneumococcal disease in hospitalized Canadian adults, and determine the proportion of cases caused by vaccine-preventable serotypes. METHODS: Active surveillance for CAPSpn and IPD in hospitalized adults was performed in hospitals across five Canadian provinces from December 2010 to 2013. CAPSpn were identified using sputum culture, blood culture, a commercial pan-pneumococcal urine antigen detection (UAD), or a serotype-specific UAD. The serotype distribution was characterized using Quellung reaction, and PCR-based serotyping on cultured isolates, or using a 13-valent pneumococcal conjugate vaccine (PCV13) serotype-specific UAD assay. RESULTS AND CONCLUSIONS: In total, 4769 all-cause CAP cases and 81 cases of IPD (non-CAP) were identified. Of the 4769 all-cause CAP cases, a laboratory test for S. pneumoniae was performed in 3851, identifying 14.3% as CAPSpn. Of CAP cases among whom all four diagnostic test were performed, S. pneumoniae was identified in 23.2% (144/621). CAPSpn cases increased with age and the disease burden of illness was evident in terms of requirement for mechanical ventilation, intensive care unit admission, and 30-day mortality. Of serotypeable CAPSpn or IPD results, predominance for serotypes 3, 7F, 19A, and 22F was observed. The proportion of hospitalized CAP cases caused by a PCV13-type S. pneumoniae ranged between 7.0% and 14.8% among cases with at least one test for S. pneumoniae performed or in whom all four diagnostic tests were performed, respectively. Overall, vaccine-preventable pneumococcal CAP and IPD were shown to be significant causes of morbidity and mortality in hospitalized Canadian adults in the three years following infant PCV13 immunization programs in Canada.
引用
- LeBlanc JJ, ElSherif M, Ye L, et al. Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. Vaccine. 2017. PMID: 28554501. doi:10.1016/j.vaccine.2017.05.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。